FUTURE-GB: functional and ultrasound-guided resection of glioblastoma – a two-stage randomised control trial. Issue 11 (15th November 2022)
- Record Type:
- Journal Article
- Title:
- FUTURE-GB: functional and ultrasound-guided resection of glioblastoma – a two-stage randomised control trial. Issue 11 (15th November 2022)
- Main Title:
- FUTURE-GB: functional and ultrasound-guided resection of glioblastoma – a two-stage randomised control trial
- Authors:
- Plaha, Puneet
Camp, Sophie
Cook, Jonathan
McCulloch, Peter
Voets, Natalie
Ma, Ruichong
Taphoorn, Martin J B
Dirven, Linda
Grech-Sollars, Matthew
Watts, Colin
Bulbeck, Helen
Jenkinson, Michael D
Williams, Matthew
Lim, Adrian
Dixon, Luke
Price, Stephen John
Ashkan, Keyoumars
Apostolopoulos, Vasileios
Barber, Vicki S
Taylor, Amy
Nandi, Dipankar - Other Names:
- author non-byline.
Critchley Giles author non-byline.
Eralil George author non-byline.
Whitehouse Kathrin author non-byline.
Solth Anna author non-byline.
Brennan Paul M author non-byline.
Rajaraman Chittoor author non-byline.
Achawal Shailendra author non-byline.
Varma Anil author non-byline.
Corns Robert author non-byline.
Sivakumar Ganamurthy author non-byline.
Olubajo Farouk author non-byline.
McKintosh Edward author non-byline.
McKenna Grainne author non-byline.
Paraskevopoulos Dimitrios author non-byline.
Barua Neil author non-byline.
Palmer James author non-byline.
Smith Stuart author non-byline.
Grundy Paul author non-byline.
Albanese Erminia author non-byline.
Chan Huan author non-byline.
Holliman Damian author non-byline.
Lavrador Jose author non-byline.
Velicu Maria author non-byline. - Abstract:
- Abstract : Introduction: Surgery remains the mainstay for treatment of primary glioblastoma, followed by radiotherapy and chemotherapy. Current standard of care during surgery involves the intraoperative use of image-guidance and 5-aminolevulinic acid (5-ALA). There are multiple other surgical adjuncts available to the neuro-oncology surgeon. However, access to, and usage of these varies widely in UK practice, with limited evidence of their use. The aim of this trial is to investigate whether the addition of diffusion tensor imaging (DTI) and intraoperative ultrasound (iUS) to the standard of care surgery (intraoperative neuronavigation and 5-ALA) impacts on deterioration free survival (DFS). Methods and analysis: This is a two-stage, randomised control trial (RCT) consisting of an initial non-randomised cohort study based on the principles of the IDEAL (Idea, Development, Exploration, Assessment and Long-term follow-up) stage-IIb format, followed by a statistically powered randomised trial comparing the addition of DTI and iUS to the standard of care surgery. A total of 357 patients will be recruited for the RCT. The primary outcome is DFS, defined as the time to either 10-point deterioration in health-related quality of life scores from baseline, without subsequent reversal, progressive disease or death. Ethics and dissemination: The trial was registered in the Integrated Research Application System (Ref: 264482) and approved by a UK research and ethics committee (Ref:Abstract : Introduction: Surgery remains the mainstay for treatment of primary glioblastoma, followed by radiotherapy and chemotherapy. Current standard of care during surgery involves the intraoperative use of image-guidance and 5-aminolevulinic acid (5-ALA). There are multiple other surgical adjuncts available to the neuro-oncology surgeon. However, access to, and usage of these varies widely in UK practice, with limited evidence of their use. The aim of this trial is to investigate whether the addition of diffusion tensor imaging (DTI) and intraoperative ultrasound (iUS) to the standard of care surgery (intraoperative neuronavigation and 5-ALA) impacts on deterioration free survival (DFS). Methods and analysis: This is a two-stage, randomised control trial (RCT) consisting of an initial non-randomised cohort study based on the principles of the IDEAL (Idea, Development, Exploration, Assessment and Long-term follow-up) stage-IIb format, followed by a statistically powered randomised trial comparing the addition of DTI and iUS to the standard of care surgery. A total of 357 patients will be recruited for the RCT. The primary outcome is DFS, defined as the time to either 10-point deterioration in health-related quality of life scores from baseline, without subsequent reversal, progressive disease or death. Ethics and dissemination: The trial was registered in the Integrated Research Application System (Ref: 264482) and approved by a UK research and ethics committee (Ref: 20/LO/0840). Results will be published in a peer-reviewed journal. Further dissemination to participants, patient groups and the wider medical community will use a range of approaches to maximise impact. Trial registration number: ISRCTN38834571 . … (more)
- Is Part Of:
- BMJ open. Volume 12:Issue 11(2022)
- Journal:
- BMJ open
- Issue:
- Volume 12:Issue 11(2022)
- Issue Display:
- Volume 12, Issue 11 (2022)
- Year:
- 2022
- Volume:
- 12
- Issue:
- 11
- Issue Sort Value:
- 2022-0012-0011-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-11-15
- Subjects:
- Neurosurgery -- Clinical trials -- SURGERY
Medicine -- Research -- Periodicals
610.72 - Journal URLs:
- http://www.bmj.com/archive ↗
http://bmjopen.bmj.com/ ↗ - DOI:
- 10.1136/bmjopen-2022-064823 ↗
- Languages:
- English
- ISSNs:
- 2044-6055
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24313.xml